Cognition Therapeutics (CGTX) Cash from Financing Activities (2020 - 2026)
Cognition Therapeutics (CGTX) posted quarterly Cash from Financing Activities of -$233000.0 for Q1 2026, down 117.98% year-over-year from $1.3 million in Q1 2025, and down 138.51% quarter-over-quarter from $605000.0 in Q4 2025.
Cognition Therapeutics (CGTX) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Cognition Therapeutics (CGTX) has reported Cash from Financing Activities for 7 consecutive years, with -$233000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 117.98% year-over-year to -$233000.0; the TTM figure through Mar 2026 stood at $35.0 million (up 172.31% YoY), while the FY2025 annual figure was $36.6 million, up 55.19% from the prior year.
- Cash from Financing Activities declined to -$233000.0 in Q1 2026 per CGTX's latest filing, from $605000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $33.9 million in Q3 2025 and bottomed at -$374000.0 in Q2 2022.
- Historically, Cash from Financing Activities has averaged $4.1 million across 5 years, with a median of $752000.0 in 2025.
- Annual changes were most pronounced in 2024 — Cash from Financing Activities soared 120030.0% — and 2026, when it sank 117.98%.
- Cognition Therapeutics' Cash from Financing Activities stood at $5.1 million in 2022, then tumbled by 52.57% to $2.4 million in 2023, then soared by 366.63% to $11.4 million in 2024, then slumped by 94.68% to $605000.0 in 2025, then tumbled by 138.51% to -$233000.0 in 2026.
- Business Quant data shows CGTX's Cash from Financing Activities at -$233000.0 in Q1 2026, $605000.0 in Q4 2025, and $33.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Cognition Therapeutics | 90.18 Mn | 90.18 Mn | - | 6.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.61 Mn |
| Jun 30, 2026 | 6.61 Mn |
| Mar 31, 2026 | -233,000.00 |
| Mar 31, 2026 | -233,000.00 |
| Dec 31, 2025 | 605,000.00 |
| Dec 31, 2025 | 605,000.00 |
| Sep 30, 2025 | 33.92 Mn |
| Sep 30, 2025 | 33.92 Mn |
| Jun 30, 2025 | 752,000.00 |
| Jun 30, 2025 | 752,000.00 |
| Mar 31, 2025 | 1.30 Mn |
| Mar 31, 2025 | 1.30 Mn |
| Dec 31, 2024 | 11.38 Mn |
| Dec 31, 2024 | 11.38 Mn |
| Sep 30, 2024 | 329,000.00 |
| Sep 30, 2024 | 329,000.00 |
| Jun 30, 2024 | -138,000.00 |
| Jun 30, 2024 | -138,000.00 |
| Mar 31, 2024 | 11.99 Mn |
| Mar 31, 2024 | 11.99 Mn |